Ambrilia: manufacture of Octreotide for acromegaly triggers milestone payment from U.S. partner

By Lisa Kerner

Charlotte, N.C., Aug. 1 - Ambrilia Biopharma Inc. received a milestone payment from its undisclosed U.S. licensing partner for manufacture of sterile batches of its late-stage oncology specialty generic, Octreotide, for the treatment of acromegaly.

The companies' agreement includes upfront payments and milestones to Ambrilia, as well as purchase of the final product.

Ambrilia will manufacture the product at its cGMP (Good Manufacturing Practices) facility in Montreal, supplying the finished product to the partner for sale in the United States, according to a company news release.

To date Ambrilia has received $2.2 million in licensing fees and milestone payments from its partner, with additional milestone payments expected over the next 20 to 24 months.

Ambrilia is conducting pivotal pharmacokinetic studies of Octreotide in comparison to Novartis' Sandostatin LAR (long-acting release) in human subjects.

"Octreotide represents an important marketing opportunity for us and our partners since the need for a sustained release formulation of the drug, for treatment of acromegaly and certain rare digestive tumors, keeps growing," president and chief executive officer Hans J. Mader said in the release.

Acromegaly is a chronic disease resulting from the growth of an adenomatous tumor on the pituitary gland.

Ambrilia is a biopharmaceutical company based in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.